News NICE breast cancer criteria missing patients, claims study NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.
News Cytokinetics' cardiomyopathy drug cleared for NHS use Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.
News As patents expire, fampridine is cleared for NHS use in MS Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.
News UK experts call for meningitis shots for all 15-year-olds All 15-year-olds in the UK should be offered the meningitis B vaccine following the fatal outbreaks earlier this year, says the JCVI.
News Bayer's Kerendia on course for NHS use in heart failure Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.
News NICE aims to cut funding for Amgen lung cancer drug Lumykras Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.